Key Takeaways Catalyst Pharmaceuticals' Q3 EPS of $0.68 beat estimates on 15% year-over-year revenue growth.Firdapse sales rose 16%, while Agamree revenues more than doubled amid strong product demand.CPRX lifted 2025 revenue guidance to $565M-$585M following strong Q3 earnings results.Catalyst Pharmaceuticals (CPRX) reported adjusted earnings of 68 cents per share for the third quarter of 2025, beating the Zacks Consensus Estimate of 51 cents. The company had recorded adjusted earnings of 57 cents in the y ...

Catalyst Pharmaceuticals (NasdaqCM:CPRX) Q3 2025 Earnings Call November 06, 2025 08:30 AM ET Speaker1Greetings and welcome to the Catalyst Pharmaceuticals Third Quarter 2025 Financial Results Conference Call and Webcast. At this time, all participants are in a listen-only mode. A question-and-answer session will follow a formal presentation. You may be placed into question queue at any time by pressing Star 1 on your telephone keypad. We ask that you please ask one question, one follow-up, then return to th ...

Catalyst Pharmaceutical (CPRX) reported $148.39 million in revenue for the quarter ended September 2025, representing a year-over-year increase of 15.3%. EPS of $0.68 for the same period compares to $0.57 a year ago.The reported revenue represents a surprise of +8.77% over the Zacks Consensus Estimate of $136.43 million. With the consensus EPS estimate being $0.51, the EPS surprise was +33.33%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they co ...

Catalyst Pharmaceutical (CPRX) came out with quarterly earnings of $0.68 per share, beating the Zacks Consensus Estimate of $0.51 per share. This compares to earnings of $0.57 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +33.33%. A quarter ago, it was expected that this specialty drug company would post earnings of $0.58 per share when it actually produced earnings of $0.68, delivering a surprise of +17.24%.Over the last fo ...

财务业绩摘要 - 2025年第三季度总营收为1.484亿美元，较2024年同期的1.287亿美元增长15.3% [9] - 2025年第三季度净产品收入为1.484亿美元，较2024年同期的1.264亿美元增长17.4% [5][9] - 2025年第三季度GAAP净收入为5280万美元（基本每股收益0.43美元，稀释后每股收益0.42美元），较2024年同期的4390万美元增长20.3% [6][11] - 2025年第三季度非GAAP净收入为8610万美元（基本每股收益0.70美元，稀释后每股收益0.68美元），较2024年同期的7110万美元增长21.2% [6][12] 产品收入表现 - FIRDAPSE在2025年第三季度创下净产品收入记录，达9220万美元，较2024年同期增长16.2%，增长动力来自新患者、剂量增加、用药持续性以及在特发性和癌症相关Lambert-Eaton肌无力综合征市场的进一步渗透 [5] - AGAMREE在2025年第三季度净产品收入为3240万美元，较2024年同期的1500万美元大幅增长115.2%，显示出在杜氏肌营养不良症卓越中心的持续需求和早期市场渗透 [5][6] - FYCOMPA在2025年第三季度净产品收入为2380万美元，较2024年同期的3210万美元下降25.8%，该业绩在首个仿制药于2025年第二季度末进入市场后仍强于最初预测 [5] 财务指引更新 - 将2025年全年总营收指引上调至5.65亿美元至5.85亿美元区间，反映业绩优于最初预测 [1][5] - 将AGAMREE的2025年净产品收入指引上调至1.05亿美元至1.15亿美元区间 [5] - 将FYCOMPA的2025年净产品收入指引上调至1亿美元至1.1亿美元区间 [5] - 重申FIRDAPSE的2025年净产品收入指引为3.55亿美元至3.6亿美元区间 [5] 业务运营亮点 - 公司宣布了一项最高2亿美元的股票回购计划，于2025年10月1日至2026年12月31日期间执行，截至2025年11月5日已回购405,092股普通股，总价约840万美元 [1][7] - 公司与Lupin就FIRDAPSE专利诉讼达成和解，Lupin获得于2035年2月开始销售仿制药的许可，目前仅剩一宗针对Hetero USA的专利案件待审 [7] - 合作伙伴KYE Pharmaceuticals获得加拿大卫生部批准在加拿大商业化AGAMREE，这是加拿大首个获批治疗杜氏肌营养不良症的疗法 [7] - 公司2025年迄今已评估超过100个临床和商业化阶段的收购目标，专注于寻找具有临床差异化并能解决未满足医疗需求的罕见病资产 [7][8] 财务状况与支出 - 截至2025年9月30日，现金及现金等价物为6.899亿美元，较2024年12月31日的5.176亿美元增长33.3% [6][13][26] - 2025年第三季度研发费用为270万美元，较2024年同期的330万美元有所减少 [10] - 2025年第三季度销售、一般和行政费用为4750万美元，较2024年同期的4590万美元略有增加 [10] - 2025年第三季度运营收入为6630万美元，较2024年同期的5090万美元增长30.2% [11]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [Mark One] Indicate by checkmark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such report(s), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR ...

CORAL GABLES, Fla., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that it has been named as one of the BioSpace 2026 Best Places to Work for the second consecutive year, ranking 13 among 30 U.S. employers in the small company category. "We are honored to ...

CORAL GABLES, Fla., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Rich Daly, President and CEO, along with other members of Catalyst's management team, will participate in the Jefferies Global Healthcare Conference in London on Monday, November 17, ...

I have a B.Tech degree in Mechanical Engineering from a top school in India. For nearly twenty five years, I have worked in the oil and gas sector, primarily in the Middle East. I work at the intersection of engineering, operations, and project management in an industry that does not forgive mistakes - so I have learned to be efficient, careful, and disciplined. These traits inform my investment strategy. For much of my professional career, I have maintained a serious and sustained interest in the U.S. equi ...

公司财务业绩发布安排 - 公司将于2025年11月5日市场收盘后发布2025年第三季度财务业绩 [1] - 管理层将于2025年11月6日东部时间上午8:30举行电话会议和网络直播，讨论财务业绩并提供业务更新 [2] 投资者交流活动详情 - 电话会议及网络直播日期为2025年11月6日，时间为东部时间上午8:30 [3] - 美国/加拿大拨入号码为877-407-8912，国际拨入号码为201-689-8059 [3] - 网络直播可在公司官网投资者栏目观看，直播回放将在网站上保留至少30天 [3] 公司业务概况 - 公司是一家专注于罕见病领域的生物制药公司，致力于改善罕见病患者的生活 [4] - 业务模式包括授权引进、商业化和开发创新疗法，并在美国拥有成熟的商业布局 [4] - 公司总部位于佛罗里达州科勒尔盖布尔斯，入选《福布斯》2025年美国最成功的中型公司榜单和2024年德勤北美增长最快500强技术企业榜单 [4]